Taking Charge of Charge Variants

A principal reason for why the manufacture of biologics is difficult is the structural complexity of the recombinant glycoproteins that are being produced.  As biologics production moves from research and…

0 Comments
Antibodies to Watch 2019: 10 Years and Counting
Monoclonal antibody (mAb or moAb), made by identical immune cells that are all clones of a unique parent cell. Most biotech drugs are monoclonal antibodies

Antibodies to Watch 2019: 10 Years and Counting

The annual “Antibodies to Watch” article series is celebrating its 10th anniversary. Published in the journal mAbs and widely anticipated at the beginning of the new year, these articles have…

0 Comments

CAR-T cells: Beyond CD19

CAR-T cells are a new and exciting drug class in which treatment involves the use of transformed immune cells for cancer therapy. A patient’s T- cells are removed, transduced and expanded…

0 Comments

Biosimilars on the Sale Rack

Biologics are the fastest-growing class of therapeutic products in the United States. As products of genetic engineering technology, they were initially introduced in the 1980s and the segment has been…

0 Comments
Close Menu